Analysis
CNBC's July 22 report on Axiom AIOSciences captures an unusual reversal in the typical IPO playbook: a US-based biotech company choosing to list in Hong Kong first, rather than pursuing a US listing as the primary or exclusive venue. Historically, US biotechs have treated Nasdaq as the default home for a public listing, with secondary listings elsewhere, if any, coming later. Axiom flipping that order is a meaningful signal about where the firm -- and its bankers -- see the friendliest combination of valuation, approval speed and investor liquidity right now.
Hong Kong's exchange has spent the past several years actively courting biotech listings specifically, building out specialized listing rules (Chapter 18A) for pre-revenue biotech companies that don't fit traditional profitability-based listing requirements. That effort is clearly working if it's now pulling in US-headquartered companies rather than just regional ones, and it puts Hong Kong in more direct competition with Nasdaq for a listing category the US exchange has dominated for decades.
“That's a meaningfully different competitive dynamic for Nasdaq and NYSE than the usual China-outbound-listing story.”
The parallel to DeepSeek's own reported path toward a mainland China STAR Market listing, rather than a US IPO, is worth drawing explicitly -- both stories this week point toward Asian listing venues actively competing for, and in some cases winning, listings that would have defaulted to US exchanges even two or three years ago. That's a meaningfully different competitive dynamic for Nasdaq and NYSE than the usual China-outbound-listing story.
For context on scale and precedent, this is a much smaller listing than the trillion-dollar SpaceX and prospective Anthropic IPOs dominating headlines this week, but it's arguably a more structurally important story for the US listing ecosystem -- it's evidence that competition for where companies choose to go public is intensifying at the mid-cap biotech level, not just at the mega-cap AI-lab level.
For biotech-focused investors and bankers, Axiom's choice is worth watching as a bellwether: if more US-headquartered biotechs start defaulting to Hong Kong or other Asian venues for their primary listing, that's a trend with real implications for where biotech IPO fee pools and aftermarket liquidity concentrate over the next several years.
